主要文件

查看所有文档

1478800

USP

奥利司他

Name: 奥利司他
Brand: USP

United States Pharmacopeia (USP) Reference Standard

别名:

N-甲酰基-L-亮氨酸（1S）-1 - [[（2S，3S）-3-己基-4-氧代-2-氧杂环丁烷基]甲基]十二烷基酯, Ro-18-0647, （−）-四氢脂抑素

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₂₉H₅₃NO₅

化学文摘社编号:

96829-58-2

分子量:

495.73

NACRES:

NA.24

PubChem Substance ID:

329750618

UNSPSC Code:

41116107

MDL number:

MFCD05662360

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

grade

pharmaceutical primary standard

API family

orlistat

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O

InChI

1S/C29H53NO5/c1-5-7-9-11-12-13-14-15-16-18-24(34-29(33)26(30-22-31)20-23(3)4)21-27-25(28(32)35-27)19-17-10-8-6-2/h22-27H,5-21H2,1-4H3,(H,30,31)/t24-,25-,26-,27-/m0/s1

InChI key

AHLBNYSZXLDEJQ-FWEHEUNISA-N

Gene Information

human ... LIPF(8513), PNLIP(5406)

说明

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Orlistat USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Biochem/physiol Actions

奥利司他用于肥胖症研究，是一种胰脂肪酶抑制剂，在胃肠道局部起作用以抑制脂肪酶。

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

Other Notes

溶液不完全澄清，小颗粒可能仍然悬浮。

Sales restrictions may apply.

Still not finding the right product?

Explore all of our products under 奥利司他

存储类别

11 - Combustible Solids

flash_point_f

Not applicable

flash_point_c

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

[Pharmacological sheet. Orlistat, oral administration (Xenical, Alli). ].

Journal de pharmacie de Belgique, (2)(2), 67-68 (2009-09-11)

Obesity management: update on orlistat.

Belinda S Drew et al.

Vascular health and risk management, 3(6), 817-821 (2008-01-19)

Over the past 20 years obesity has become a worldwide concern of frightening proportion. The World Health Organization estimates that there are over 400 million obese and over 1.6 billion overweight adults, a figure which is projected to almost double

Orlistat-associated adverse effects and drug interactions: a critical review.

Theodosios D Filippatos et al.

Drug safety, 31(1), 53-65 (2007-12-22)

Orlistat, an anti-obesity drug, is a potent and specific inhibitor of intestinal lipases. In light of the recent US FDA approval of the over-the-counter sale of orlistat (60 mg three times daily), clinicians need to be aware that its use

查看所有相关文献

全球贸易项目编号

货号	GTIN
1478800-200MG	04061838737694